Second-line and later treatment options for synovial sarcoma are limited. Afamitresgene autoleucel is the first FDA-approved T-cell receptor therapy, demonstrating long-lasting responses and tolerable adverse effects in pretreated patients.
Lauren Bivacca, PharmD, MBA
Advertisement
Articles by Lauren Bivacca, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Once-Weekly Retatrutide Reduces Weight and Knee Pain in Patients With Obesity and Osteoarthritis
2
How Pharmacists Can Close the Opioid Addiction Care Gap
3
FDA Approval Signals Broader Recognition of Sexual Health in Aging Women
4
FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced HER2+ Breast Cancer
5
